-
Dementia rising
Thursday | Feb 5 2026THE number of Australians living with dementia in 2026 has increased to an estimated 446,500, and is expected to double to more than one million people by 2065.
-
Food for the skin
Thursday | Feb 5 2026WELEDA’S much-loved Skin Food range now includes the new Skin Food Body Wash Shower Cream (RRP $19.95), gently cleansing the skin while offering instant nourishment and hydration.
-
Guidelines unclear 05 Feb 26
Thursday | Feb 5 2026PHARMACISTS are calling for “simpler, clearer” guidelines around prescribing the morning-after pill, with new research showing many default to the cheaper LNG option despite it being less effective than UPA.
-
PD for Thu 05 Feb 2026
Thursday | Feb 5 2026UNSW tackles pharmacy skills shortage, pharmacists call for clearer morning-after pill guidelines, Pride-focused pharmacy conference announced, and more
-
Guild’s $5k bursary for rural pharmacists
Wednesday | Feb 4 2026THE Pharmacy Guild of Australia and Rural Pharmacists Australia have launched the Rural Pharmacy Forum Bursary to help eligible rural pharmacists attend APP2026, which takes place from 12-14 Mar on the Gold Coast.
-
APP exhibition sold out
Wednesday | Feb 4 2026THE Australasian Pharmacy Professional Conference and Trade Exhibition (APP) has announced its 2026 Trade Exhibition is now fully allocated, with exhibition stands sold out for next month’s event.
-
Sunscreen recalls
Wednesday | Feb 4 2026THE Therapeutic Goods Administration (TGA) has issued recall alerts for several sunscreen products.
-
Guild Victoria welcomes ADHD reforms
Wednesday | Feb 4 2026THE Pharmacy Guild of Australia, Victoria Branch, has welcomed the Victorian Government’s announcement that GPs who undertake accredited training will be able to diagnose and treat ADHD in children and adults.
-
PD for Wed 04 Feb 2026
Wednesday | Feb 4 2026Guild’s $5k bursary for rural pharmacists, APP2026 trade exhibition sold out, initiative seeks to advance responsible AI in healthcare, and more
-
Sandoz expands biosimilar access
Tuesday | Feb 3 2026SANDOZ has announced the listing of the first aflibercept biosimilar, AFQLIR, on the Pharmaceutical Benefits Scheme (PBS), improving access to ophthalmology treatments for Australians living with multiple neovascular-related conditions.
PARTNER SITES
to top